IDiyas

For the Inventor, By the Inventor

Bethany, CT, United States of America

Lawrence R Marcin

USPTO Granted Patents = 16 

 

Average Co-Inventor Count = 5.1

ph-index = 5

Forward Citations = 58(Granted Patents)


Company Filing History:

goldMedal15 out of 3,681 
 
Bristol-myers Squibb Compnay
 patents
silverMedal1 out of 41 
 
Bristol Meyers Squibb Company
 patents

Years Active: 2004-2023

Loading Chart...
Loading Chart...
16 patents (USPTO):Explore Patents
1. 11639353 - Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors (2023-05-02),
2. 11014922 - Cyclobutane- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors (2021-05-25),
3. 10112944 - Heterocyclic compounds useful as inhibitors of TNF (2018-10-30),
4. 9738642 - Triazolopyridine ether derivatives and their use in neurological and pyschiatric disorders (2017-08-22),
5. 8604024 - Compounds for the reduction of beta-amyloid production (2013-12-10),
6. 8513253 - α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors (2013-08-20),
7. 8350084 - Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production (2013-01-08),
8. 8349880 - Bicyclic compounds for the reduction of beta-amyloid production (2013-01-08),
9. 7902218 - Substituted tetrahydroisoquinolines as β-secretase inhibitors (2011-03-08),
10. 7786122 - α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors (2010-08-31),
11. 7772221 - Diaminopropane derived macrocycles as inhibitors of β amyloid production (2010-08-10),
12. 7338974 - Macrocyclic diaminopropanes as beta-secretase inhibitors (2008-03-04),
13. 7300936 - α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors (2007-11-27),
14. 7105516 - Compounds for the treatment of premature ejaculation (2006-09-12),
15. 7084178 - Antiamyloid phenylsulfonamides: N-cycloalkylcarboxamides derivatives (2006-08-01),

Title: The Innovative Contributions of Lawrence R Marcin

Introduction

Lawrence R Marcin is a notable inventor based in Bethany, CT (US), recognized for his significant contributions to the field of pharmaceuticals. With a total of 16 patents, Marcin has made strides in developing compounds that target various medical conditions.

Latest Patents

Among his latest patents, Marcin has developed cyclobutanes- and azetidine-containing mono and spirocyclic compounds that serve as αV integrin inhibitors. These compounds are designed to act as antagonists to αV-containing integrins, which play a crucial role in several diseases. The invention also encompasses pharmaceutical compositions that utilize these compounds, providing methods for treating conditions associated with dysregulation of αV-containing integrins, including pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders.

Career Highlights

Throughout his career, Marcin has worked with prominent companies, including Bristol-Myers Squibb Company. His work has significantly impacted the pharmaceutical industry, particularly in the development of innovative treatments.

Collaborations

Marcin has collaborated with esteemed colleagues such as John E Macor and Mendi A Higgins, contributing to the advancement of research and development in his field.

Conclusion

Lawrence R Marcin's innovative work and numerous patents highlight his dedication to improving medical treatments and addressing critical health issues. His contributions continue to influence the pharmaceutical landscape significantly.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…